My Favorites
My Favorites
Add Page
Add Page
Print
Print
You have 0 items saved in "My Favorites"
Use "My Favorites" to collect pages, downloads, properties, and companies that you would like to keep in one place. To store a page, click on the "Add to My Favorites" button at the top of the page. To store a download, click on the plus button next to the download link. To store a property or company or community, click on the "Add to My Favorites" button listed next to each listing. My Favorites will be saved for seven days.
NEWS FEED
Monday, November 03, 2014
CSL Behring plans $240 million expansion at its Kankakee operations center


Published at Area Development Online 10/8/14

 
A leader in the plasma protein therapeutics industry, CSL Behring plans a $450 million, two-site, global expansion at its production facilities in Kankakee, Illinois, and Melbourne, Australia.
 
According to the firm, its production expansion is designed to meet a growing need for its lifesaving and life-improving therapies, used to treat patients with rare and serious medical disorders around the world.
 
CSL Behring plans production capacity increases of plasma intermediates at its Kankakee site and albumin at its Broadmeadows facility in Australia. At Kankakee, the expansion will substantially increase the production of plasma intermediates. CSL Behring uses plasma intermediates to make albumin and immunoglobulins. The expansion is expected to be completed in 2017, at which time 300,000 square feet will have been added to the site. Of the $450 million investment, $240 million will be for Kankakee and $210 million for Broadmeadows.
 
The announcement follows the U.S. Food and Drug Administration's recent regulatory approval to commence operations from a previous expansion of Kankakee's manufacturing operation, which added 140,000 square feet.
 
The cross-functionality that is enabled by the capacity expansions will allow CSL Behring to leverage its global manufacturing network, helping to optimize the manufacturing efficiencies of immunoglobulin and albumin. "Our latest production expansion means the critical base material for our leading therapies will continue to be available - enabling us to deliver on our promise to patients around the world," said CEO Paul Perreault.
 
Click here to read full article at original source.